Document Detail


Pharmacotherapy of obesity.
MedLine Citation:
PMID:  17115344     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Obesity has become a significant health problem in industrialised and developing countries, and despite all nutritional and behavioural approaches, its prevalence is still increasing. In recent years, the identification and characterisation of central and peripheral mechanisms involved in the regulation of energy balance has made remarkable progress and provided numerous targets for novel anti-obesity agents. However, only few anti-obesity drugs are on the market and not many compounds have entered clinical development. In the present review, the clinically available agents are discussed and their pharmacological profiles are compared. Some of the drugs that are currently in clinical development are mentioned as examples of the possible future range of anti-obesity agents. Selected topics in drug discovery are presented to illustrate novel targets and concepts for the pharmacotherapy of obesity.
Authors:
K G Hofbauer; J R Nicholson
Related Documents :
8984744 - Urinary bladder function and drug development.
17880834 - How to choose the initial drug treatment for overactive bladder.
9724 - Disorders of micturition: neuropharmacologic basis and results of drug therapy.
16925744 - Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: moto...
11570594 - Preparation by spray drying of amphotericin b-phospholipid composite particles and thei...
17629304 - In silico prediction of ionization constants of drugs.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association     Volume:  114     ISSN:  0947-7349     ISO Abbreviation:  Exp. Clin. Endocrinol. Diabetes     Publication Date:  2006 Oct 
Date Detail:
Created Date:  2006-11-20     Completed Date:  2007-02-01     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9505926     Medline TA:  Exp Clin Endocrinol Diabetes     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  475-84     Citation Subset:  IM    
Affiliation:
Applied Pharmacology, Biozentrum/Pharmazentrum, University of Basel, Basel, Switzerland. karl.hofbauer@unibas.ch
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Anti-Obesity Agents / therapeutic use*
Clinical Trials as Topic
Cyclobutanes / therapeutic use
Drug Design
Energy Metabolism / drug effects
Homeostasis / drug effects
Humans
Lactones / therapeutic use
Life Style
Models, Biological
Obesity / drug therapy*,  surgery
Piperidines / therapeutic use
Pyrazoles / therapeutic use
Technology, Pharmaceutical / trends
Chemical
Reg. No./Substance:
0/Anti-Obesity Agents; 0/Cyclobutanes; 0/Lactones; 0/Piperidines; 0/Pyrazoles; 106650-56-0/sibutramine; 158681-13-1/rimonabant; 96829-58-2/orlistat

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The effect of capecitabine on the healing of colonic anastomoses in rats.
Next Document:  Evaluation of the diagnostic value of the first thyroglobulin determination in detecting metastases ...